Blackwell Kimberly 4
4 · Zentalis Pharmaceuticals, Inc. · Filed Dec 2, 2021
Insider Transaction Report
Form 4
Blackwell Kimberly
Director
Transactions
- Sale
Common Stock
2021-12-01$81.84/sh−1,000$81,840→ 5,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-12-01−1,000→ 39,000 totalExercise: $47.80Exp: 2030-06-30→ Common Stock (1,000 underlying) - Exercise/Conversion
Common Stock
2021-12-01$47.80/sh+1,000$47,800→ 6,000 total
Footnotes (2)
- [F1]The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 20, 2021.
- [F2]The options vest and become exercisable in substantially equal monthly installments over the 36 months following the date of grant, July 1, 2020.